OncoMatch/Clinical Trials/NCT04625907
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
Is NCT04625907 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments for rhabdomyosarcoma.
Treatment: Irinotecan · Actinomycin D · Doxorubicin · Ifosfamide · Vincristine · Vinorelbine · Cyclophosphamide · Temozolomide · Regorafenib — FaR-RMS is an over-arching study for children and adults with newly diagnosed and relapsed rhabdomyosarcoma (RMS)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Rhabdomyosarcoma
Demographics
Prior therapy
Cannot have received: stem cell transplant
Prior allo- or autologous Stem Cell Transplant
Cannot have received: regorafenib (regorafenib)
Prior regorafenib
Cannot have received: temozolomide (temozolomide)
Prior temozolomide
Lab requirements
Blood counts
Absolute neutrophil count ≥1.0x 10^9/L; Platelets ≥ 80 x 10^9/L
Kidney function
estimated or measured creatinine clearance ≥60 ml/min/1.73 m2
Liver function
Total bilirubin ≤ 1.5 x ULN for age (unless Gilbert's syndrome); ALT or AST < 2.5 x ULN for age (IRIVA); ALT or AST >3.0 x ULN [excluded, CT3]; Bilirubin, Total >1.5 x ULN [excluded, CT3]; total bilirubin is allowed up to 3 x ULN if Gilbert's syndrome is documented
Cardiac function
Fractional Shortening ≥ 28% (CT1a); Absence of severe vincristine neuropathy; No unstable angina, recent MI, cardiac failure NYHA ≥2, congestive heart failure (Modified Ross ≥2), or cardiac arrhythmias requiring antiarrhythmic therapy (CT3)
Adequate hepatic function: Total bilirubin ≤ 1.5 x ULN for age (unless Gilbert's syndrome); ALT or AST < 2.5 x ULN for age; Absolute neutrophil count ≥1.0x 10^9/L; Platelets ≥ 80 x 10^9/L; Adequate renal function: estimated or measured creatinine clearance ≥60 ml/min/1.73 m2; Fractional Shortening ≥ 28%; Absence of severe vincristine neuropathy; No unstable angina, recent MI, cardiac failure NYHA ≥2, congestive heart failure (Modified Ross ≥2), or cardiac arrhythmias requiring antiarrhythmic therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04625907 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior stem cell transplant, regorafenib, temozolomide disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 25 years or younger and at least 0.5 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages